Journal of Clinical Immunology

J Clin Immunol. 2026 Jan 6. doi: 10.1007/s10875-025-01972-1. Online ahead of print. ABSTRACT Patient-reported outcomes are critical to multidisciplinary, patient-centred approaches in diseases requiring lifelong management. Among inborn errors of immunity (IEIs), reports on this subject are typically limited to specific diagnostic subgroups or focus narrowly on the route of immunoglobulin replacement therapy (IgRT), offering … Read more

J Clin Immunol. 2026 Jan 2. doi: 10.1007/s10875-025-01973-0. Online ahead of print. ABSTRACT The tumor necrosis factor (TNF) receptor superfamily member, transmembrane activator and CAML interactor (TACI) encoded by TNFRSF13B, are extensively involved in immune responses. In our previous work, TNFRSF13B exon 2 variants were recurrently identified in chronic active Epstein-Barr virus disease (CAEBV). Here … Read more

J Clin Immunol. 2025 Dec 27. doi: 10.1007/s10875-025-01975-y. Online ahead of print. NO ABSTRACT PMID:41454991 | DOI:10.1007/s10875-025-01975-y

J Clin Immunol. 2025 Dec 27. doi: 10.1007/s10875-025-01974-z. Online ahead of print. ABSTRACT OBJECTIVE: The presence of unique monocyte subsets and sub-populations plays a significant role in the onset and progression of rheumatic diseases. This study aimed to characterize variations in monocyte subsets and sub-populations and functional roles in patients with primary Sjögren’s syndrome (pSS) … Read more

J Clin Immunol. 2025 Dec 26. doi: 10.1007/s10875-025-01955-2. Online ahead of print. ABSTRACT Type II interferon (IFN) immunity is crucial for controlling intramacrophagic infections, driven by the interaction between innate immunity (macrophage-derived IL-12) and adaptive immunity (Th-derived IFN-γ). This study examines the maturation of type II IFN immunity in 55 healthy children (ages 1-18) to … Read more

J Clin Immunol. 2025 Dec 24. doi: 10.1007/s10875-025-01977-w. Online ahead of print. ABSTRACT Trained immunity, a de-facto innate immune memory, has been extensively studied in response to live-attenuated vaccines, but its presence following the new COVID-19 vaccines has not yet been fully elucidated. In this study, we investigate markers of trained immunity in individuals vaccinated … Read more

J Clin Immunol. 2025 Dec 13. doi: 10.1007/s10875-025-01971-2. Online ahead of print. NO ABSTRACT PMID:41390883 | DOI:10.1007/s10875-025-01971-2

J Clin Immunol. 2025 Dec 12. doi: 10.1007/s10875-025-01970-3. Online ahead of print. ABSTRACT INTRODUCTION: Primary ‘predominantly antibody deficiencies’ (PADs) are rare disorders characterized by increased susceptibility to infections, autoimmunity, allergies, and malignancies. Their low prevalence and heterogeneity often delay diagnosis, increasing morbidity and mortality. This study identifies infection patterns in PAD patients and analyzes predictors … Read more

J Clin Immunol. 2025 Dec 10. doi: 10.1007/s10875-025-01969-w. Online ahead of print. ABSTRACT PURPOSE: Long COVID (LC) is a long-term debilitating disease of which the exact pathophysiology is unknown. A dysregulated immune response resulting in hyperresponsive immune cells is hypothesized as a key mechanism in the development of LC. Several studies suggest that acute infections … Read more

J Clin Immunol. 2025 Nov 28. doi: 10.1007/s10875-025-01966-z. Online ahead of print. ABSTRACT PURPOSE: Despite well-conducted replacement therapy with polyvalent immunoglobulins (IgRT), some patients with primary immunodeficiencies (PID) continue to experience recurrent or chronic infections. IgA and IgM, essential for mucosal and complement-mediated immunity, are absent or minimal in standard immunoglobulin products. The aim of … Read more